Tuberous sclerosis cost-effectiveness of therapy

Tuberous sclerosis Microchapters
Home
Patient Information
Overview
Historical Perspective
Pathophysiology
Differentiating Tuberous sclerosis from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Criteria
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Tuberous sclerosis cost-effectiveness of therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Tuberous sclerosis cost-effectiveness of therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Tuberous sclerosis cost-effectiveness of therapy
CDC on Tuberous sclerosis cost-effectiveness of therapy
Tuberous sclerosis cost-effectiveness of therapy in the news
Blogs on Tuberous sclerosis cost-effectiveness of therapy
Directions to Hospitals Treating Tuberous sclerosis
Risk calculators and risk factors for Tuberous sclerosis cost-effectiveness of therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

A study from 2016 showed that for children with TSC presenting with refractory epilepsy (defined by the persistence of seizures despite the use of 2 anti-seizure drugs), the most cost-effective measure berween resective epilepsy surgery, vagus nerve stimulator implantation, ketogenic diet, and addition of a third anti-seizure drug, was the addition of a third drug into the medication regimen,